- The FDA has granted 510(k) clearance for Apyx Medical Corporation’s (NASDAQ:APYX) Renuvion for subcutaneous dermatological and aesthetic procedures to improve the appearance of lax skin in the neck and submental region.
- Renuvion is a proprietary helium plasma and radiofrequency technology.
- Related: Apyx Medical Posts Encouraging Data From Renuvion Device In Sagging Skin.
- This clearance offers a new option for physicians and patients to improve loose skin on the neck and submental region.
- With this clearance, Renuvion is the only product that is FDA-cleared to improve the appearance of loose skin on the neck and chin.
- Renuvion provides a minimally-invasive and cost-effective option with minimal downtime. The results reveal a more contoured and smoother neck and jawline.
- Price Action: APYX shares are up 9.20% at $8.31 during the market session on the last check Monday
What’s Going On With AMD Stock Thursday?
Advanced Micro Devices, Inc (NASDAQ: AMD) stock is trading higher Thursday after crucial supplier Taiwan Semiconductor Manufacturing Company Ltd (NYSE: TSM) reported upbeat quarterly
